Drug Trial Radar · NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
893
Planned (sponsor's estimate)
Start
Oct 4, 2021
Primary completion
Feb 26, 2026
Study completion May 31, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
subcutaneous
DaratumumabDrug
Daratumumab / hyaluronidase, subcutaneous
PomalidomideDrug
oral
DexamethasoneDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Safety Lead-In: Incidence of dose limiting toxicitiesTime frame: First 42 days after first elranatamab dose
- Part 2 Randomized: Progression free survival per International Myeloma Working Group criteriaTime frame: From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months
- Part 3: Frequency of treatment-emergent adverse eventsTime frame: First 84 days after first elranatamab dose
Locations
237 sites in 26 countries. Site status is shown where the registry gives one.
Clovis Community Medical Center
Clovis, California · Active not recruiting
Community Cancer Institute
Clovis, California · Active not recruiting
University of California San Francisco
Fresno, California · Active not recruiting
Community Regional Medical Center
Fresno, California · Active not recruiting
UCHealth Poudre Valley Hospital
Fort Collins, Colorado · Active not recruiting
UCHealth Harmony
Fort Collins, Colorado · Active not recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Active not recruiting
UCHealth - Medical Center of the Rockies
Loveland, Colorado · Active not recruiting
Sylvester Comprehensive Cancer Center - Aventura
Aventura, Florida · Recruiting
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
Coral Gables, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Coral Springs
Coral Springs, Florida · Recruiting
University of Miami Hospital and Clinics - Deerfield Beach
Deerfield Beach, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Hollywood
Hollywood, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Kendall
Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Plantation
Plantation, Florida · Recruiting
East Jefferson General Hospital
Metairie, Louisiana · Active not recruiting
MSK Basking Ridge
Basking Ridge, New Jersey · Recruiting
MSK Monmouth
Middletown, New Jersey · Recruiting
MSK Bergen
Montvale, New Jersey · Recruiting
MSK Commack
Commack, New York · Recruiting
MSK Westchester
Harrison, New York · Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York · Recruiting
MSK Nassau
Uniondale, New York · Recruiting
Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Terminated
FUNDALEU - Fundacion para combatir la Leucemia
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
FUNDALEU -Fundación para combatir la leucemia
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
FUNDALEU
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina · Active not recruiting
Hospital Universitario Austral
Presidente Derqui, Buenos Aires, Argentina · Active not recruiting
Sanatorio de La Mujer
Rosario, Santa Fe Province, Argentina · Active not recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
QScan Radiology Clinics
Clayfield, Queensland, Australia · Recruiting
Gallipoli Medical Research Foundation
Greenslopes, Queensland, Australia · Active not recruiting
Greenslopes Private Hospital
Greenslopes, Queensland, Australia · Active not recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Epworth Freemasons
East Melbourne, Victoria, Australia · Recruiting
St Vincent's Hospital (Melbourne)
Fitzroy, Victoria, Australia · Recruiting
Showing 40 of 237 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.